Speaker Gallery

“The immune biology of microsatellite instability in cancer: towards a vaccine against HNPCC”
Prof. Magnus von Knebel Doeberitz
University of Heidelberg, Heidelberg, Germany

“Inducing neoantigens in therapeutic and prophylactic cancer immunotherapy”
Prof. Eli Gilboa
UM/Sylvester Comprehensive Cancer Center at the Miller School of Medicine, University of Miami

“Diabetes, beta-cells and reprogramming with mRNA: potential cell-based therapy for diabetes”
Dr. Tomáš Koblas
Clinical Islet Laboratory, Department of Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

“Characterizing mRNA-based therapeutics and vaccines: from single molecules to the whole body”
Prof. Philip J. Santangelo
Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, USA

“Abrogation of the immunosuppressive tumor-microenvironment in Hepatocellular Carcinoma by targeting Treg and co-inhibitory pathways”
Dr. Jaap Kwekkeboom & Dr. Dave Sprengers
Erasmus MC-University Medical Centre, Rotterdam

“Exploiting Natural Killer Cells for Immunotherapy of Cancer”
PD Dr. Adelheid Cerwenka
Innate Immunity Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

“Regulation of tumor immunity by macrophage and eosinophils”
Prof. Günter Hämmerling
Division of Molecular Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany

“Assessment of proliferative activity in breast cancer as a basis for individualized treatment decisions”
Prof. Hans-Anton Lehr
Institut für Pathologie im Medizin Campus Bodensee, Germany

“Therapeutic applications of nucleoside modified mRNA”
Prof. Drew Weissman
University of Pennsylvania, USA

“Activating NK cell receptors in immunosurveillance of cancer cells”
Prof. Joachim Koch
Georg-Speyer-Haus, Frankfurt, Germany

“Principles of TNF receptor activation and their exploitation for the development of TNF receptor-targeting drugs”
Prof. Harald Wajant
Division of Molecular Internal Medicine, University Hospital Würzburg, Germany

“A shot in the arm towards effective HIV vaccines”
Prof. Robin Shattock
Imperial College London, UK

Prof. Dr. G. Hartmann
Dept. of Clinical Chemistry and Pharmacology at University Medical Center Bonn, Germany

“TEIPP – T Cell Epitopes associated with Impaired Peptide Processing”
Dr. Thorbald van Hall
LUMC (Leids Universitair Medisch Centrum), Leiden, Netherlands

“TEIPP – T Cell Epitopes associated with Impaired Peptide Processing”
Prof. Dr. Sjoerd H. van der Burg
LUMC (Leids Universitair Medisch Centrum), Leiden, Netherlands

“Origin, complexity and impact of DNA structural rearrangements in cancer”
Jan Korbel
Group Leader – Genome Biology (EMBL) Heidelberg, Germany

“Induction of regulatory T cells by soluble CD83 – Modulation of the immune system in autoimmunity and transplantation”
Prof. Dr. Alexander Steinkasserer
Head – Dept. of Immune Modulation, Erlangen, Germany

Prof. Dr. Philipp Beckove
DKFZ, Division of Translational Immunology, Heidelberg, Germany

“Animal Models”
Prof. Ferdinando Nicoletti
OncoNOx, Copenhagen, Denmark

“Unsupervised clustering and supervised classification for the automated analysis of flow cytometry data”
Richard Scheuermann, PhD
J. Craig Venter Institute, Director of Informatics, San Diego, USA

“Regulation of T lymphocyte function in tumors”
Pierre van der Bruggen, PhD
de Duve Institute, Brussels, Belgium

“Regulation of T lymphocyte function in tumors”
Prof. Dr. med. Michael Platten
Department of Neurooncology, Ruprecht-Karls University Heidelberg, Germany

“Challenges and opportunities of a next generation dendritic cell cancer vaccine: pre-clinical and clinical overview”
Prof. Dr. Ada Kruisbeek
Founder and CSO of DCPrime BV, Leiden, Netherlands

“Making biomarkers functional – a path towards personalized medicine” 
Matthew L. Albert
Director of Dept of Immunology, Institut Pasteur, Paris, France

“Role of BCL9 proteins in Wnt-mediated stem cell maintenance”
Prof. Dr. Michel Aguet
National Center of Competence in Research (NCCR) “Molecular Oncology”, Lausanne, Switzerland

“Tetramere validation and new targets in oncology” 
Ronald Rooke, PhD
Transgene SA, Illkirch Graffenstaden Cedex, France

“Autoimmunity in Oncology:
From epitope profiling to
vaccination studies”

Prof. Dr. Hans-Jürgen Thiesen
Institut für Immunologie Universität Rostock

“Tumor-host immune interactions and their prognostic/predictive significance” 
Prof. Dr. med. Dirk Jäger
Director Medical Oncology, National Center for Tumor Diseases, University Medical Center Heidelberg

Epigenetic Regulation of Cellular Differentiation
Dr. Vijay Tiwari
Institute of Molecular Biology gGmbH, Mainz, Germany

Targeting cell death pathways for cancer therapy
Prof. Dr. med. Simone Fulda
Institute for Experimental Cancer Research in Pediatrics, J.W. Goethe University Hospital Frankfurt am Main, Germany

Anticalins: antibodies of a new kind through protein design
Prof. Dr. Arne Skerra
Technische Universität München, Lehrstuhl für Biologische Chemie, Germany

An insight on therapeutic cancer vaccines
Dr. Sonia Quaratino
Merck KGaA, Darmstadt, Germany

Genomic analysis of tumour infection & immunity
Dr. Robert Holt
Canada’s Michael Smith Genome Sciences Centre, Vancouver, Canada

Targeted Resequencing: recent advances in amplicon sequencing and library prep technology
James Hadfield
Head of Genomics Core Facility, Cancer Research UK, Cambridge Research Institute, UK

Molecular cancergenetics
Dr. Tobias Sjöblom
Department of Immunology, Genetics and Pathology Uppsala University, Rudbeck Laboratory SE-751 85 Uppsala, Sweden

CARs with extraordinary performance: chimeric antigen receptor redirected T cells to fight cancer
Prof. Dr. med. Hinrich Abken
Tumorgenetik, Klinik 1 für innere Medizin und Zentrum für molekulare Medizin, Universität zu Köln, Germany

Pancreatic Cancer
Dr. Anna Melissa Schlitter
Institut für Pathologie Technische Universität München, Germany

Therapeutic Genome Engineering with Designer Nucleases
Prof. Dr. Toni Cathomen
Medizinische Hochschule Hannover, Institut für Experimentelle Hämatologie, Hannover, Germany

Turning genomic junk into treasure: Genetic engineering with Sleeping Beauty transposons
Prof. Dr. Zoltan Ivics
Paul-Ehrlich-Institut, Experimental Research in the Division of Medical Biotechnology, Langen, Germany

Intratumoral Immune Reaction. A Novel Paradigm for Cancer
Dr. Jerôme Galon
Inserm U872, Integrative Cancer Immunology Laboratory, Paris, France

Evolution of the Cancer Genome
Prof. Mike Stratton
Wellcome Trust Sanger Institute, Cambridge, UK

Nicolae Ghinea, PhD
National Institute of Health and Medical Research (INSERM), Paris, France